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Introduction: Synovial sarcoma is a high-grade, soft-tissue sarcoma that most frequently is located in the vicinity of
joints, tendons or bursae, although it can also be found in extra-articular locations. Most patients with synovial
sarcoma of the hand are young and have a poor prognosis, as these tumors are locally aggressive and are
associated with a relatively high metastasis rate. According to the literature, local recurrence and/or metastatic
disease is found in nearly 80% of patients. Current therapy comprises surgery, systemic and limb perfusion
chemotherapy, and radiotherapy. However, the 5-year survival rate is estimated to be only around 27% to 55%.
Moreover, most authors agree that synovial sarcoma is one of the most commonly misdiagnosed malignancies of
soft tissues because of their slow growing pattern, benign radiographic appearance, ability to change size, and the
fact that they may elicit pain similar to that caused by common trauma.
Case presentation: We describe an unusual case of a large synovial sarcoma of the hand in a 63-year-old
Caucasian woman followed for 12 years by a multidisciplinary team. In addition, a literature review of the most
pertinent aspects of the epidemiology, diagnosis, treatment and prognosis of these patients is presented.
Conclusion: Awareness of this rare tumor by anyone dealing with hand pathology can hasten diagnosis, and this,
in turn, can potentially increase survival. Therefore, a high index of suspicion for this disease should be kept in
mind, particularly when evaluating young people, as they are the most commonly affected group.
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Synovial sarcoma of the hand is an extremely rare entity
that carries a worse prognosis than that of most soft-
tissue sarcomas [1,2]. It has been estimated that, on
average, even hand surgeons will encounter only one or
two undiagnosed soft-tissue sarcomas of the upper ex-
tremity during the entire duration of their careers [1].
In addition, the majority of authors agree that synovial
sarcoma is one of the most commonly misdiagnosed
malignancies of the soft tissues, owing to its slow grow-
ing pattern, benign radiographic appearance, ability to
change size, and their often eliciting pain similar to that
caused by common trauma [3,4]. Hence, synovial sar-
coma patients are often diagnosed initially as having* Correspondence: mmmouzinho@sapo.pt
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reproduction in any medium, provided the ormyositis, hematoma, synovitis, tendonitis, bursitis or
other common disorders [3,4].
To make matters worse, primary synovial sarcoma size
and initial status at presentation have been shown to
strongly affect survival [3,5]. Therefore, a high index of
suspicion for this disease should be kept in mind, par-
ticularly when evaluating young people, as they are the
most commonly affected group [3,4]. Herein we describe
the clinical case of a large synovial sarcoma of the hand
in a 63-year-old woman followed up for 12 years. More-
over, a brief review of this unusual sarcoma is presented.
Case presentation
A 63-year-old, right-handed Caucasian woman with an
unremarkable medical history was referred to the hand
clinic at our institution with a large firm mass in her left
hand that had been growing steadily over the previous
3 years (Figures 1 and 2). The mass had grown to a point
that it interfered with many of her daily life activities.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Palmar aspect of the left hand showing a large
nodular mass over the first four rays.
Figure 3 Magnetic resonance image of a coronal section of the
hand showing a large mass around the palmar structures of
the hand, but with no bone involvement.
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the first three rays of the hand. Ultrasound examination
was inconclusive. Magnetic resonance imaging (MRI)
was performed, which revealed a large mass spanning al-
most the entire palmar aspect of the hand, superficially
to the flexor tendons and with no evidence of bone in-
volvement (Figures 3 and 4). A pre-operative angiogram
showed a tumor with a rich blood supply (Figure 5). The
tumor vessels were given off by the deep palmar arch,
the external branch of the superficial palmar arch and
the palmar digital arteries of the first, second and third
fingers. With the patient under local anesthesia, an inci-
sional biopsy was performed, which identified a synovial
sarcoma.
Subsequently, with the patient under general anes-
thesia, the mass was excised via a palmar approach, pre-
serving the flexor apparatus of the fingers as well as
all major vessels and nerves (Figures 6 and 7). Macro-
scopically, the tumor was grayish and had a maximumFigure 2 Dorsal aspect of the hand with the protruding mass in
the first and second interdigital web spaces preventing
complete finger adduction.length of approximately 10cm (Figure 6). The tumor was
multinodular and rubbery and seemed to be circum-
scribed by a fibrous pseudocapsule. The post-operative
period was uneventful. Recovery was fast, and the pa-
tient had no significant functional or aesthetic impair-
ment (Figure 8). She declined any physiotherapy
treatments. Her only complaint was pain over theFigure 4 Magnetic resonance image of a transverse section of
the hand showing a large mass around the palmar structures
of the hand, but with no bone involvement.
Figure 5 Pre-operative angiogram showing the rich blood
supply to the tumor, arising from the deep palmar arch, from
the external branch of the superficial palmar arch and from the
palmar digital arteries of the first, second and third fingers.
Figure 7 At the end of the surgery, all digits were spared.
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post-operatively. Pathological examination revealed the
typical appearance of synovial sarcoma of the monophasic
type (Figure 9). The specimen margins were found free of
tumor cells. There was no evidence of systemic disease on
the computed tomography (CT) scan of the thorax, abdo-
men and pelvis that had been done pre-operatively. The
patient underwent post-operative radiotherapy and chemo-
therapy with good tolerance. Adjuvant chemotherapy con-
sisted of one cycle of ifosfamide and doxorubicin following
the recommendations described by Kampe et al. [6]. Ifosfa-
mide was given for 6 days at a dose of 14g/m2. AnFigure 6 Intraoperative view of the excised specimen.equimolar dose of mesna was combined with the first dose
of ifosfamide of 2g/m2. These two drugs were given as a
4-hour intravenous bolus. The subsequent ifosfamide
treatment was given at the rate of 2g/m2/24 hours by con-
tinuous intravenous infusion. The patient received an add-
itional dose of mesna at the end of the sixth day.
Doxorubicin was administered as a 48-hour continuous
intravenous infusion, corresponding to a total dose of
60mg/m2. Adjuvant radiotherapy was delivered at the end
of chemotherapy, including not only the tumor excision
site but also a 3cm margin. A total dose of 60 Gy was ap-
plied, fractioned in 2.0 Gy daily, 5 days per week, during
6 weeks.
The patient was followed at the hand clinic at regular
intervals for 9 years. The CT scans of the thorax, abdomen
and pelvis that were done regularly during this period
failed to show any evidence of systemic disease. She then
decided to stop coming to the outpatient clinic, arguing
that she saw no point in going as she felt perfectly well.
Eleven and one-half years after surgery, the patient
returned to the outpatient clinic with a recurrence of a
sarcomatous mass in her left hand. MRI of the hand
showed a large hypervascular mass with foci of necrosis
that occupied most of the anterior compartments of the
hand and encroached into the metacarpal and carpal
bones (Figure 10). No evidence of metastasis was found.
A multidisciplinary team decided to propose left-hand
amputation, which the patient declined. Twelve years after
the initial diagnosis, she decided to stop coming to the out-
patient clinic again and rebuffed any further contact. Six
months later, she was found dead at her home, having had
a massive hemorrhage from the recurrence in her hand.
Discussion
Synovial sarcomas are malignant, high-grade, soft-tissue
neoplasms that are estimated to represent between 5%
and 10% of all soft-tissue sarcomas [3,7]. The estimated
Figure 8 One month post-operatively, the patient had a good functional and aesthetic result.
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per 100,000 [3]. In fact, in adults, synovial sarcoma is
the fourth most common type of sarcoma after malig-
nant fibrous histiocytoma, liposarcoma and rhabdomyo-
sarcoma [3]. In the United States alone, approximately
800 new cases are diagnosed each year [3,7]. In children,
synovial sarcoma incidence is second only to rhabdo-
myosarcoma in terms of soft-tissue sarcoma [8]. Ap-
proximately one-third of synovial sarcomas occur in the
first two decades of life [3,7,8]. This tumor is most
prevalent in adolescents and adults between 15 and 40
years of age [3,7,8]. Concerning gender incidence, the
male:female ratio is 1.2:1, with males being more fre-
quently affected. Synovial sarcoma has a similar inci-
dence in all ethnic groups [2,3,7,8].
This malignancy is usually located close to the large
joints of the extremities, especially the lower extremities
and in particular around the knee and ankle [2,3,7,8].
Other joints that are commonly affected are the shoul-
der and the hip. Most often it arises in the para-articular
regions, usually in close association with tendon sheaths,
bursae and joint capsules [2,3,7,8]. However, it seldom
involves the joints themselves [3]. In addition, contrary
to what its name might suggest, synovial sarcoma also
occurs in areas with no apparent relation to synovial
structures, such as the heart, pericardium, pleura, lung,
mediastinum, larynx, peritoneal cavity and abdominal
wall [3]. In the hand, this tumor is more frequently
found in the carpal region than in the fingers [2,3,7,8].
According to most authors, delay in diagnosis is very
frequent [3]. In the majority of cases, the presence of a
clinically detectable tumor prior to surgery is esti-
mated to range from 2 to 4 years, but an insidiously
growing mass or pain at the tumor site has been noted
for as long as 20 years prior to initiation of proper
treatment [3,4]. Recently, it has been shown that the
occurrence of long-standing pain at the tumor site pre-
ceding the development of a bulge is significantly more
common with synovial sarcomas than with other sar-
comas [9]. The imaging appearance is nonspecific, and
in all cases a biopsy is necessary to confirm the diagno-
sis [3,10,11].Histologically, synovial sarcoma is typically character-
ized by epithelium-like and/or spindle cell components
arranged in a biphasic or monophasic pattern, although
a poorly differentiated variant has also been described
recently [12]. The biphasic pattern is considered the
“classic” type and is generally recognizable by the coex-
istence of morphologically different but genetically simi-
lar epithelial cells and fibroblast-like spindle cells [3].
The monophasic type is closely related to the biphasic
type and represents merely one extreme of its morpho-
logical spectrum, sharing phenotypical features identical
to the spindle-cell portion or the epithelium-like compo-
nent, corresponding to the monophasic fibrous variant
or to the monophasic epithelial variant, respectively [3].
Histologically, the poorly differentiated type is composed
mostly of small, solidly packed, oval or spindle-shaped cells
that seem to have an intermediate phenotype between epi-
thelial and spindle cells, often with scant differentiation,
simulating other neoplasms, namely, angiosarcoma or
small-cell carcinoma [3].
Immunohistochemically, the majority of synovial sar-
comas express cytokeratins, epithelial membrane anti-
gen, calponin, B-cell lymphoma 2 (BCL-2) and CD-99.
Vimentin can also be found in the spindle cells of these
tumors. These markers can help differentiate synovial
sarcomas from other sarcomas [12,13].
Although microscopic resemblance to the developing
synovium was initially suggested, its origin from pre-
formed synovial tissues remains to be proven [12,13].
Owing to the similarity between synovial sarcoma tumor
cells and primitive synoviocytes, the term synovial sar-
coma was coined [12,13]. However, most of these tumors
occur outside the joints themselves and bear no resem-
blance to synovial structures either ultrastructurally or
immunohistochemically [12]. It has been proposed that
synovial sarcoma arises from the pluripotential mesen-
chyme of the limb bud [3].
A particular chromosomal translocation t(X;18) has
been noted in over 90% of cases, both in adults and in
children [12,14]. Although synovial sarcomas can be
graded histologically according to mitotic index, percent-
age of necrosis and tumor differentiation, almost all
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as high-grade sarcomas [12,14].
Synovial sarcomas not only are locally aggressive but
also have a higher metastatic potential than most other
soft-tissue sarcomas. Hence, the overall prognosis for
synovial sarcoma patients is poor [2,8,12]. In fact,
according to most reports, notwithstanding intensiveFigure 9 (See legend on next page.)multimodal therapy, including surgery, chemotherapy
and radiotherapy, the outcomes of these patients have
changed little in the past two decades [3,15]. According
to the literature, local recurrence and/or metastatic dis-
ease are found in nearly 80% of patients [2,8,12,15]. Sev-
eral factors have been associated with a higher
recurrence risk. These factors include older age, larger
(See figure on previous page.)
Figure 9 Histological appearance of the tumor. (A) Photomicrograph of a low-power magnification (40×) of a hematoxylin and eosin-stained
section showing numerous highly packed cells forming densely cellular sheets and vague fascicles. (B) High-power magnification (400×)
photomicrograph showing a hematoxylin and eosin-stained section with spindle cells with oval nuclei and scarce cytoplasm. These cells are
uniform and relatively small, characterizing the monophasic “fibrous variant” of synovial sarcoma. (C) High-power magnification (400×)
photomicrograph of a hematoxylin and eosin-stained section showing focal areas of a prominent hemangiopericytomatous vascular pattern,
which is a frequent finding in synovial sarcoma. (D) Intermediate-power magnification (100×) photomicrograph of a hematoxylin and eosin-
stained section showing focal tumor calcifications (arrows), which is also a relatively frequent finding in these tumors. (E) High-power
magnification (400×) photomicrograph of an immunohistochemical section marking epithelial membrane antigen outlining the surface of the
sarcomatous cells, which is typical of synovial sarcoma. (F) Intermediate-power magnification (100×) photomicrograph of an
immunohistochemical section marking cytokeratin 7 (CK7) showing CK7-positive cells either isolated or in cords. (G) High-power magnification
(400×) photomicrograph of an immunohistochemical section marking CD99, which is staining the surfaces of tumor spindle cells. (H) High-power
magnification (400×) photomicrograph of an immunohistochemical section marking B-cell lymphoma 2 (BCL-2), showing diffuse staining of the
tumor.
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in the limbs, male sex, bone or neurovascular invasion,
incomplete excision on pathological examination, p53
overexpression, high proliferative index and, more re-
cently, specific SYT-SSX fusion types [16,17]. Our pa-
tient presented with only two of these risk factors, which
may help explain the unusual long survival time
observed. The most common site for metastasis is theFigure 10 Magnetic resonance imaging scan of the hand
showing tumor recurrence with a large hypervascular mass and
foci of necrosis that occupied most of the anterior
compartments of the hand and encroached into the
metacarpal and carpal bones.lung [4,18]. Lymph node involvement has been reported
to occur in as many as 27% of patients [18].
Surgical resection is the definitive choice of treatment
for primary synovial sarcomas and has been shown to
both control local recurrence and prevent systemic dis-
semination [2,8,12]. Unfortunately, the minimal accept-
able margin has not been clearly established, and the
surgeon must be aware of the possibility of microscopic
infiltration of tumor cells into the pseudocapsule of the
tumor [1,3,10]. Many investigators have suggested 1 cm
to 2cm resection margins [1-3,10]. Because of proximity
to the joints, the ablation can consist of either tenosyno-
vectomy and/or post-operative radiotherapy and/or
chemotherapy, or simply extremity segment amputation
[3]. If ablation and tenosynovectomy are selected to re-
tain maximal function, there might be a compromise of
soft-tissue cover over tendons and neurovascular pedi-
cles [3]. When proximity to critical anatomical struc-
tures and patient desire do not allow the surgeon to
obtain adequate surgical margins, isolated limb perfusion
and radiotherapy must be considered, as they can poten-
tially prevent amputation. In all cases, multidisciplinary
discussion of adjuvant therapies that may prevent ampu-
tation must occur prior to surgery [1-3,10,18]. Flaps are
also an important option to bear in mind, as they can
provide coverage of vital anatomical structures, as well
as minimize the effects of radiation injury on these
structures [19]. Discussion of the most adequate curative
procedure, knowledge of the available reconstructive
options, consideration of possible comorbidities and pa-
tient wishes for limb preservation must all be taken into
account before surgery [19].
The efficacy of adjuvant chemotherapy is still a matter
of intense debate [18]. Similarly, radiotherapy is asso-
ciated with a higher rate of local disease control, but not
with better survival rates [3,18].
The presence of metastasis is considered the major
cause of poor outcome, and several reports describing
the results of current therapy showed a 5-year survival
rate of around 27% to 55% [2,8,12]. Factors determining
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equate surgical resection, local recurrence, patient age
over 20 years, monophasic variant and high mitotic ac-
tivity [2,5,8,15]. Therefore, such a prolonged longevity as
we observed in our patient is unfortunately not the most
common result [3].
Conclusion
Awareness of this rare tumor by anyone dealing with
hand pathology can hasten diagnosis, and this, in turn,
can potentially increase survival [9]. Therefore, a high
index of suspicion for this disease should be kept in
mind, particularly when evaluating young people, as this
is the most commonly affected group [3,7-9].
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